Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial

Meletios A Dimopoulos, MD, Katja Weisel, MD, Philippe Moreau, Larry Anderson, MD PhD, Darrell J White, MD, Jesus F San-Miguel, MD PhD, Pieter Sonneveld, MD PhD, Monika Engelhardt, MD, Matthew W Jenner, Alessandro Corso, MD, Jan Dürig, Michel Pavic, MD, Morten Salomo, Xin Yu, Tuong Vi Nguyen, Amine Bensmaine, Teresa Peluso, Mohamed Zaki, MD PhD, Paul Richardson

Blood (2018) 132 (Supplement 1): 3278.

https://doi.org/10.1182/blood-2018-99-111869

Published: 2018

Journal Articles

Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study

Blood (2018) 132 (Supplement 1): 1960.

https://doi.org/10.1182/blood-2018-99-112155

Published: 2018

Journal Articles

Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis

Sundar Jagannath, MD, Craig C. Hofmeister, MD, David S. Siegel, MD, PhD, Ravi Vij, MD, Sagar Lonial, MD, Kenneth C. Anderson, MD, Min Chen, PhD, Mohamed Zaki, MD, Paul G. Richardson, MD

Blood (2012) 120 (21): 450.

https://doi.org/10.1182/blood.V120.21.450.450

Published: 2012

Journal Articles

Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study

Meletios A. Dimopoulos, MD, Martha Q Lacy, MD, Philippe Moreau, MD, Katja C Weisel, MD, Kevin W. Song, MD, FRCPC, Michel Delforge, MD, PhD, Lionel Karlin, MD, Hartmut Goldschmidt, MD, Anne Banos, MD, Albert Oriol, MD, Xin Yu, PhD, Lars Sternas, MD, Christian J. Jacques, MD, Mohamed Zaki, MD, Jesús F San Miguel, MD, PhD

Blood (2012) 120 (21): LBA-6.

https://doi.org/10.1182/blood.V120.21.LBA-6.LBA-6

Published: 2012

Journal Articles

Improvement in Clinical Benefit Parameters with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results From a Phase 2 Study

Sagar Lonial, MD, Rachid Baz, MD, Nizar J. Bahlis, MD, Christine I. Chen, MD, Kenneth C. Anderson, MD, Min Chen, PhD, Mohamed Zaki, MD, Paul G. Richardson, MD

Blood (2012) 120 (21): 4052.

https://doi.org/10.1182/blood.V120.21.4052.4052

Published: 2012

Journal Articles

Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT)

Paul G. Richardson, MD, Andrzej Jakubowiak, MD, PhD, Nizar J. Bahlis, MD, David S. Siegel, MD, PhD, Christine I. Chen, MD, Min Chen, PhD, Mohamed Zaki, MD, Gail Larkins, RN, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 4053.

https://doi.org/10.1182/blood.V120.21.4053.4053

Published: 2012

Journal Articles

Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure

Ravi Vij, MD, Craig C. Hofmeister, MD, Paul G. Richardson, MD, Sundar Jagannath, MD, David S. Siegel, MD, PhD, Rachid Baz, MD, Min Chen, PhD, Mohamed Zaki, MD, Gail Larkins, RN, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 4070.

https://doi.org/10.1182/blood.V120.21.4070.4070

Published: 2012

Journal Articles

Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes

David S. Siegel, MD, PhD, Paul G. Richardson, MD, Rachid Baz, MD, Min Chen, PhD, Mohamed Zaki, MD, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 4072.

https://doi.org/10.1182/blood.V120.21.4072.4072

Published: 2012

Journal Articles

Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results

Paul G. Richardson, MD, David S. Siegel, MD, PhD, Ravi Vij, MD, Craig C. Hofmeister, MD, Sundar Jagannath, MD, Christine Chen, MD, Sagar Lonial, MD, Andrzej J Jakubowiak, MD, PhD, Nizar J Bahlis, MD, Rachid Baz, MD, Gail Larkins, RN, Min Chen, PhD, Mohamed Zaki, MD, PhD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 634.

https://doi.org/10.1182/blood.V118.21.634.634

Published: 2011

Journal Articles

Simulation of Clinical Outcome for Pomalidomide Plus Low-Dose Dexamethasone in Patients with Refractory Multiple Myeloma Based on Week 8 M-Protein Response

Rene Bruno, PhD, Fredrik Jonsson, PhD, Mohamed Zaki, MD, PhD, Christian Jacques, MD, Arlene S Swern, PhD, Paul G. Richardson, MD, Vincent Rajkumar, MD, Laurent Claret, PhD

Blood (2011) 118 (21): 1881.

https://doi.org/10.1182/blood.V118.21.1881.1881

Published: 2011

Journal Articles

A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib

Paul G Richardson, MD, David Siegel, MD, PhD, Rachid Baz, MD, Susan L. Kelley, MD, Nikhil C. Munshi, MD, Daniel Sullivan, MD, Melissa Alsina, MD, Deborah Doss, RN, OCN, Laura McBride, Gail Larkins, RN, Maria Lizza, BS, Xin Yu, Mohamed Zaki, MD, Christian J. Jacques, MD, Kenneth C. Anderson, MD

Blood (2010) 116 (21): 864.

https://doi.org/10.1182/blood.V116.21.864.864

Published: 2010

Journal Articles

CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) - Preliminary Results of Subjects with Castleman’s Disease from a Phase 1 Study in Selected Hematological Malignancies.

Frits VanRhee, MD, PhD, FRCPath, MRCP, Luis Fayad, MD, Hossein Borghaei, OD, MS, Peter M. Voorhees, MD, Robert Z. Orlowski, MD,PhD, Richard R. Furman, MD, Mohamed Zaki, MD,PhD, Uma Prabhakar, Trina Jiao, Christine Lihou, Carlos A. Garay, MD, Razelle Kurzrock, MD, FACP

Blood (2006) 108 (11): 2728.

https://doi.org/10.1182/blood.V108.11.2728.2728

Published: 2006

NARROW

Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial

Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study

Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis

Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study

Improvement in Clinical Benefit Parameters with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results From a Phase 2 Study

Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure

Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes

Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results

Simulation of Clinical Outcome for Pomalidomide Plus Low-Dose Dexamethasone in Patients with Refractory Multiple Myeloma Based on Week 8 M-Protein Response

CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) - Preliminary Results of Subjects with Castleman’s Disease from a Phase 1 Study in Selected Hematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only